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Background: Buddleja crispa Benth (Buddlejaceae) is a dense shrub; several species of genus Buddleja have been
used in the management of various health conditions including pain and inflammation. The present study was
aimed to investigate the analgesic, anti-inflammatory and anti-platelet properties of B. crispa.
Methods: Male rats (220–270 gm,) and mice (25–30 gm) were randomly divided into different groups (n = 6).
Various doses of plant extract of B. crispa, its fractions and pure compounds isolated from the plant were
administered intraperitoneally (i.p). The analgesic, anti-inflammatory and anti-platelet activities were assessed using
acetic acid and formalin-induced nociception in mice, carrageenan-induced rat paw edema and arachidonic
acid-induced platelets aggregation tests.
Results: The intraperitoneal administration of the methanolic extract (50 and 100 mg/kg), hexane fraction (10 and
25 mg/kg i.p) exhibited significant inhibition (P < 0.01) of the acetic acid-induced writhing in mice and attenuated
formalin-induced reaction time of animals in second phase of the test. Pure compounds BdI-2, BdI-H3 and BH-3
isolated from B. crispa produced significant (P < 0.01) analgesic activity in acetic acid-induced and formalin tests. The
crude extract of B. crispa (50–200 mg/kg i.p.) and its hexane fraction inhibited carrageenan-induced rat paw edema
with maximum inhibition of 65 and 71 % respectively (P < 0.01). The analgesic and anti-inflammatory effect of
the plant extract and isolated pure compounds were comparable to diclofenac sodium. B. crispa plant extract
(0.5–2.5 mg/mL) produced significant anti-platelet effect (P < 0.01) with maximum inhibition of 78 % at 2.5 mg/ml.
Conclusion: The findings from our present study suggest that B. crispa possesses analgesic, anti-inflammatory and
anti-platelet properties. B. crispa could serve a potential novel source of compounds effective in pain and
inflammatory conditions.
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Buddleja crispa Benth (Buddlejaceae) is a dense shrub
endemic in Indo-Pak. The genus Buddleja comprises
about 100 species found in the warmer parts of Southern
Asia, Africa and America. The genus has diverse medi-
cinal uses and several of its species have been used in a
variety of health conditions worldwide [1]. B. asiata, in-
digenous to China and India is known for its use as an
abortifacient and for treatment of skin diseases. The
aqueous extract of B. globase is used for stomach ulcers,* Correspondence: sultanmeo@hotmail.com
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Chile. B. officinalis has a long traditional use as an adju-
vant treatment of inflammatory and neuronal diseases in
Korea and China [2].
Various species of genus Buddleja have been reported
for pharmacological activities. B. crispa has shown blood
pressure lowering, spasmolytic [3], antioxidant and
lipoxygenase inhibitory effects [4]. B. scordioides exhib-
ited gastroprotective, anti-inflammatory and antioxidant
effects [5]. Inhibition of lipopolysaccharide-induced pro-
inflammatory responses by B. officinalis has also been
reported [2]. B. cordata possesses neuroprotective prop-
erties [6]. The phytochemical studies on genus Buddleja
have revealed the isolation of various natural products,
including sterols, aryl esters, triterpenoid glycosides,is distributed under the terms of the Creative Commons Attribution 4.0
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esters [9] and diterpenes [10]. Some new constituents,
such as buddlejoside (iridoid galactoside), buddlejone
(sesquiterpene), aryl esters along with known com-
pounds, β-sitosterol and ursolic acid have been isolated
from B. crispa [4].
Owing to the diverse medicinal uses of the genus
Buddleja in inflammatory conditions and the phyto-
chemical diversity of the genus which is rich in flavo-
noids and terpenoids, the present study was undertaken
to evaluate the analgesic and anti-inflammatory potential
of B. crispa extract and some of its pure compounds,
BdI-H3, BdI-2 and BH-3.
Methods
Plant material
The plant material was collected from Baluchistan in
March 2003 and identified as B.crispa Benth., by Tax-
onomist at the Department of Botany, University of
Baluchistan, Pakistan. A voucher specimen (BBU-101) was
deposited at the herbarium of the same Department.
Extraction and fractionation
The plant material (40 kg) was cleaned, shade dried,
coarsely ground and soaked in 70 % aqueous-methanol
for 7 days with occasional shaking. It was first filtered
through a muslin cloth and then through a filter paper.
This procedure was repeated thrice and the filtrate was
combined and evaporated on rotary evaporator under
reduced pressure (−760 mmHg) at 35–40 °C to obtain a
thick, semi-solid mass of dark brown color; i.e. the crude
extract (Bc.Cr), yielding approximately 800 gm. Approxi-
mately 250 gm of the crude extract of Buddleja crispa
(Bc.Cr) was dissolved in about 300 mL of distilled water
for fractionation with hexane, chloroform and Ethyl
acetate. Pure compounds, Bdl-2, Bdl-H3 and BH-3 were
isolated from B. crispa.
Animals
Male NMRI mice (25–30 gm) and Sprage-Dawley rats
(220–270 gm) obtained from the animal house facility of
The Aga Khan University, Karachi and animal house facil-
ity of College of Medicine, King Saud University Riyadh,
Saudi Arabia respectively. Animals were housed in plastic
cages (6 rats per cage) under standard condition with 12 h
light: dark cycle with free access to food and water.
Chemicals
Acetic acid, arachidonic acid, carrageenan, diclofenac so-
dium and indomethacin were purchased from the Sigma
Chemical Co., (St. Louis Mo, USA). Formalin 37 % was
obtained from Fluka Chemie, Switzerland respectively.
All other chemicals used in experiments were of analyt-
ical grade.Experimental Methods
Acute toxicity tests
Male mice (20–25 gm) were injected intraperitoneally
(i.p) different doses of the B. crispa extract (50, 100, 300,
500, 1000 and 2000 mg/kg; n = 6) for observation. The
animals were observed for 1–2 h after administration of
the extract for any acute signs of behavioral toxicity. The
number of deaths counted at 48 h after treatment. Dose
of the extracts producing mortality in the 50 % of the
experimental animals (LD50) was determined by graph-
ical method [11].
Writhing test
Male mice (20–25 gm) were used in this experiment.
30 min. after the administration of B. crispa (50 and
100 mg/kg i.p), mice were administered an i.p. injection
of 0.7 % v/v acetic acid solution. The mice were placed
individually in transparent cages and 5 min were allowed
to elapse. The number of acid-induced writhes were
counted for 20 min. For the purpose of scoring, a writhe
was indicated by stretching of the abdomen and/or sim-
ultaneous stretching of at least one hind limb. Control
animals were injected normal saline (10 ml/kg, i.p.),
diclofenac (10 mg/kg, i.p.) was used as a standard drug.
Formalin test
This test was performed according to method described
by Hunskaar and Hole (1987) [12] male mice (20–25
gm) were injected, 20 μl of 1 % formalin prepared in
0.9 % saline, subcutaneously into the dorsal hind paw
and transferred immediately in transparent box for ob-
servation. The duration of reaction time (paw licking or
biting) was determined between 0–5 min (first phase)
and 15–30 min (second phase) after formalin injection.
Animals were administered different doses of B. crispa
plant extract (50 and 100 mg/kg i.p.) or diclofenac
(10 mg/kg, i.p.). Control animals received the vehicle
(normal saline; 0.1 ml/10 gm). The reaction time of the
animals was compared to control group and expressed
as percent inhibition.
Anti-inflammatory activity
The carrageenan induced hind paw edema test was con-
ducted according to the method of Winter et al. (1962)
[13]. Male Rats (180–250 gm) divided randomly into dif-
ferent groups (n = 5–8) and injected 0.05 ml of freshly
prepared 1 % carrageenan subcutaneously into the plan-
tar surface of the hind paw of rats. Different doses of
plant extract or diclofenac sodium were injected i.p.,
30 min before the administration of carrageenan. The
control animals received same volume of the vehicle
(Saline or distilled water 1 ml/kg). Rat paw edema was
assessed by volume displacement method (plethysm-
ometer (Ugo Basile 7150) before and after carrageenan
Table 1 Effect of B. crispa extracts and some pure compounds
isolated from the plant on acetic acid induced writhing in mice
Treatment Dose (mg/kg) Number of writhing % Protection
Control - 73 ± 7 -
B. crispa 50 33 ± 5** 54
100 26 ± 3*** 64
Hexane fraction 10 32 ± 2*** 56
25 21 ± 2*** 71
Aqueous fraction 50 38 ± 3** 48
BdI-2 5 35 ± 3** 52
10 18 ± 5*** 75
BdI-H3 1 49 ± 5* 33
5 24 ± 4*** 67
BH-3 5 56 ± 6 23
10 48 ± 4* 34
Diclofenac sodium 10 30 ± 6*** 59
20 13 ± 5*** 82
Values represent e mean ± S.E.M of 6-20 observations
*P < 0.05
**P < 0.01
***P < 0.001, compared to control
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ume, determined before and after injection of the phlo-
gistic agent indicated the severity of edema. The %
inhibition of the inflammation was determined for each
animal by comparison with controls and calculated by
the formula [14], % I = 1- (dt/ dc) x 100
Where “dt” is the difference in paw volume in the drug
treated group and “dc” the difference in paw volume in
control group and “I” = inhibition.
Anti-platelet effect
The anti-platelet activity of B. cripa was studied according
to the method as described by Saeed et al. (1995) [15].
Blood was taken by venepuncture from normal volunteers
who had not taken any medication for 1 week. Blood sam-
ples were mixed with 3.8 % (w/v) sodium citrate solution
(9:1) and centrifuged at 260 gm for 15 min at 20 °C to ob-
tain platelet rich plasma (PRP). Platelet poor plasma (PPP)
was prepared by centrifugation of the the remaining blood
sample at 1200 gm for 10 min. The aggregation studies
were carried out at 37 °C. The aggregation was monitored
with dual channel Lumi Aggregometer using 450 μl sam-
ples of PRP. The PRP was pre-incubated with appropriate
amount of the test sample for 1 min. before challenge with
aggregating agent (arachidonic acid). Aggregation was in-
duced by arachidonic acid (0.8 mM) which was expressed
as percentage inhibition compared with control at 5 min
after challenge. Test samples were solubalized in 0.9 % sa-
line or 10 % DMSO and this concentration did not inter-
fere with platelet aggregation.
Ethical approval
The study protocol (08-ECACU-BBS-13) was approved
by the Ethics Committee for Animal Care and Use
(ECACU) of the Aga Khan University, Karachi, Pakistan.
Statistical analysis
The results of the study are expressed as mean ± S.E.M
and statistical significance between control and treated
groups was evaluated by one-way analysis of variance
(ANOVA) followed by Tukey–Kramer multiple compari-
son test. P < 0.05 was considered statistically significant.
Results
Acute toxicity test
The intra-peritoneal administration of various dose of
the plant extracts did not cause any lethality up to
1000 mg/kg. LD50 value of B. crispa was 1830 mg/kg.
Animals showed hypo-motility, drowsiness at the dose
range of 500–2000 mg/kg.
Writhing test
As summarized in Table 1, the intraperitoneal (i.p)
administration of the methanolic extract of B. crispa(25–100 mg/kg) caused significant inhibition (P < 0.01;
P < 0.001) of the nociception induced by acetic acid.
The plant extract produced maximum protection of
64 % at the dose of 100 mg/kg. The results were
comparable to standard drug diclofenac sodium that
produced 59 % inhibition at 10 mg/kg i.p (Table 1).
Among the various fractions the hexane fraction of B.
crispa was the most potent with maximum protection of
71 % obtained at 25 mg/ kg. Aqueous fraction of the
plant produced 48 % protection at 50 mg/kg. The anal-
gesic potency of hexane fraction of B. crispa was 4-fold
greater than its parent crude extract. The investigation
of pure compounds isolated from the this plant i.e. BdI-
2 (steroidal galacotside), BdI-H3 and BH-3 (aryl esters)
exhibited significant analgesic effect (P < 0.01) against
acetic acid-induced pain (Table 1).
Formalin test
In the formalin test the plant extract of B. crispa (50
and100 mg/kg i.p) caused significant (P < 0.001) inhib-
ition in the second phases of formalin induced pain.
Maximum inhibition of 61 % was obtained at 100 mg/kg
i.p in the second phase of formalin test (Table 2). B.
crispa plant extract was ineffective in the first phase of
formalin test. Similarly diclofenac sodium (10 mg/kg i.p)
suppressed the reaction time of the animals in the sec-
ond phase of the test only (Table 2). As shown in Table 2,
the pure compounds BdI-2 (steroidal galacotside), BdI-
H3 and BH-3 (aryl esters) isolated from the plant caused
Table 2 Effect of B. crispa and some pure compounds isolated
from the plant in formalin test in mice
Treatment Dose
(mg/kg) i.p.
Licking time (Sec) % Inhibition
1st Phase 2nd Phase 1st Phase 2nd Phase
Control - 50 ± 3 75 ± 5 - -
B. crispa 50 55 ± 3 42 ± 5** - 44
100 51 ± 4 29 ± 5*** - 61
Hexane
fraction
10 47 ± 3 39 ± 5** 6 48
25 52 ± 5 32 ± 6*** - 57
Aqueous
fraction
50 43 ± 3 51 ± 5** 14 32
BdI-2 10 47 ± 5 25 ± 4*** - 67
-
BdI-H3 1 49 ± 6 53 ± 3* - 29
5 55 ± 7 46 ± 7** 38
BH-3 10 42 ± 7 37 ± 5** 16 50
Diclofenac
sodium
20 47 ± 5 27 ± 6*** - 64
Values represent mean ± S.E.M of 6–30 observations
*P < 0.05
**P < 0.01
***P < 0.001, compared to control
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animals in the second phase of the test.
Anti-inflammatory activity
The subplantar injection of carrageenan produced a local-
ized edema that reached to its maximum at the 3rd hour
after injection. As shown in Table 3, B. crispa (50–
200 mg/kg i.p.) caused significant inhibition (P < 0.001) of
the carrageen induced inflammation. The maximum anti-
inflammatory effect of the plant extract was 65 % at
200 mg/kg i.p. (Table 3). The anti-inflammatory effect of
plant extract was evident at 3rd hour after carrageenan in-
jection. Similarly diclofenace sodium and indomethacin,Table 3 Effect of B. crispa and its fractions on carrageenan induced
Treatment Dose (mg/kg) i.p Initial paw volume (ml)
Control - 0.96 ± 0.01
B. crispa 50 0.94 ± 0.03
100 0.96 ± 0.04
200 0.93 ± 0.03
Hexane fraction 50 0.95 ± 0.01
100 0.95 ± 0.03
Aqueous fraction 50 0.98 ± 0.02
Diclofenac sodium 20 0.98 ± 0.04
Indomethacin 20 0.96 ± 0.01
Values represent mean ± S.E.M of 6–30 observations
P < 0.05
** P < 0.01
*** P < 0.001, compared to controlused as standard anti-inflammatory drugs, at 20 mg/kg i.p.
produced about 76 and 59 % inhibition of the carrageenan
induced edema respectively (Table 3). As shown in Table 3,
Among various fractions of B. crispa, only hexane fraction
exhibited significant (P < 0.01) anti-inflammatory activity
which was comparable to crude extract of the plant.Anti-platelet effect
The inhibitory effect of B. crispa extract against platelet
aggregation was assessed in the in-vitro experiments using
arachidonic acid (AA) as the aggregating agent. pre-
incubation of platelet rich plasma with crude extracts of
B. crispa for 1 min. inhibited AA-induced platelet aggrega-
tion in dose dependent manner (Figs. 1 and 2). B. crispa
extract (2.5 mg/ml) reduced platelet aggregation to 22 ± 3
(75 % inhibition) with IC50 value of 0.54 mg/ml, Fig. 2.Discussion
Various member of genus Buddleja including B. globase
and B. officinalis are used in traditional medicine in the
management of pain and inflammatory conditions [2].
The current study was planned to explore B. crispa, the
least investigated plant of the genus, for possible anal-
gesic and anti-inflammatory effects in animal model of
pain and inflammation. The methanolic extract of the
plant and its hexane fraction caused significant inhib-
ition (P < 0.01) of the acetic acid induced writhes. Acetic
acid increases the prostaglandins levels in the peritoneal
fluid [16, 17] and commonly employed tool for screening
analgesic agents. Diclofenac sodium, a standard non-
steroidal anti-inflammatory, produced similar results,
suggesting that the inhibitory effects of B. crispa plant
extract against acetic acid induced writhing may have
occurred through inhibition of prostaglandins action. Sev-
eral medicinal plants used as analgesic such as Moringa
oleifera [18], Asparagus pubescens [19] and Melastomapaw edema in rats
Paw volume at 3 hr Increase in paw volume % Inhibition
1.13 ± 0.05 0.170 -
1.04 ± 0.03 0.10** 41
1.02 ± 0.03 0.06*** 65
0.99 ± 0.05 0.06*** 65
1.03 ± 0.02 0.08** 53
1.0 ± 0.01 0.05*** 71
1.09 ± 0.02 0.11 15
1.02 ± 0.03 0.04*** 76
1.03 ± 0.02 0.07** 59















Fig. 1 Tracing showing the inhibitory effect of crude extract of B.
crispa (Bc.Cr) against arachidonic acid (0.8 mM) induced platelet
aggregation. The platelet rich human plasma was incubated with
different doses of the plant extracts or vehicle (control) for 1 min.
before the addition of arachidonic acid
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inal stretching /constriction induced by acetic acid.
The acetic acid induced writing test is effective but it is
non-selective [21]. Acetic acid indirectly releases endogen-
ous mediators which stimulate neurons that are sensitive



















Fig. 2 Inhibitory effect of crude extracts of B. crispa (Bc.Cr) on
arachidonic acid induced platelets aggregation. Values represent the
mean ± S.E.M of the % aggregation of the control maximum (n = 3-4),
**P < 0.01 and ***P <0.001, compared to controldrugs. The analgesic effect of B. crispa plant extract was
therefore further investigated in the formalin test.
Formalin induced pain model is helpful to elucidate
the mechanism of pain and analgesia [22]. Formalin test
involves two distinct phases of analgesia, in the first
phase (neurogenic phase) pain is produced due to direct
stimulation of the sensory nerve fiber by formalin and in
the second or late phase (inflammatory phase) the pain
occurs due to release of inflammatory mediators such as
histamine, prostaglandin and bradykinin [23]. It is well
documented that centrally acting drugs such as narcotics
inhibit both phases equally while peripherally acting
drugs such as diclofenac inhibit the late phase [24–26].
In this study B. crispa produced marked analgesia in the
second phase of the test similar to diclofenac, suggesting
that peripheral mechanism is involved in analgesic effect
of the plant extract. The predominant inhibitory effect
of plant extract in the second phase of formalin test sug-
gests that the anti-nociceptive effect of plant extract oc-
curred via inhibition of prostaglandins synthesis [22].
The analgesic potency of hexane fraction of B. crispa
was 4-fold greater than its parent crude extract and the
aqueous fraction had weak inhibitory effect, showing the
analgesic constituents concentrated in the hexane frac-
tion. The investigation of pure compounds i.e. BdI-2
(steroidal galacotside), BdI-H3 and BH-3 (aryl esters) iso-
lated from B. crispa exhibited profound analgesic activity
in acetic acid induces pain and also in the late phase of
formalin test, suggesting that these constituents contrib-
ute to the observed analgesic effect of the plant extract.
The marked inhibitory effect of plant extract of B. crispa
and its fractions in the second phase of formalin test, simi-
lar to diclofenac, indicates its peripheral anti-inflammatory
effect [23]. Therefore, the anti-inflammatory effect of B.
crispa was assessed in carrageenan-induced inflammatory
edema in the hind paw of rats. Carrageenan, a mucopolysa-
charide derived from Irish Sea moss Chondrus, is used to
induce experimental arthritis. It is non-antigenic and does
not produce any systemic effects [13]. The intraperitoneal
administration of the methanolic extract of B. crispa
caused significant (P < 0.001) inhibition of the late phase
edema induced by the sub-plantar injection of carrageenan
with no inhibitory effect in the initial phase of the test.
Carrageenan produces acute inflammation believed to be
biphasic; the early phase (1-2 h after carrageenan injec-
tion), in which the edema production is mediated by hista-
mine and serotonin and the late phase (after 2nd h) the
vascular permeability is maintained by bradykinin and
prostaglandins [27]. These mediators contribute in the in-
flammatory response and induce pain [28]. It has been
shown that the second phase of carrageenan-induced
edema is sensitive to clinically used anti-inflammatory
drugs and commonly employed to assess the anti-
phlogistic effect of the natural products [29, 30]. In the
Bukhari et al. BMC Complementary and Alternative Medicine  (2016) 16:79 Page 6 of 7present study the plant extract of B. crispa and its hexane
fraction exhibited marked anti-inflammatory activity in the
late phase of carrageenan induced edema test.
Similarly non-steroidal anti-inflammatory (NSAIDs)
drugs diclofenac sodium and indomethacin produced sig-
nificant (P < 0.001) anti-edematous effect which is consist-
ent with the previous reports [31]. Several studies have
revealed the inhibitory effects of plant extracts and NSAIDs
in animal models of pain and inflammation [32–34]. It is
known that diclofenac, and aspirin suppress inflammation
and pain by inhibiting prostaglandin synthesis via inhibition
of cyclooxygenase in arachidonic acid pathways [35]. The
plant extract of B. crispa inhibited arachidonic acid induced
platelet aggregation which further strengthening the
NSAIDs like properties of of the plant extract.
Conclusion
The plant extract and hexane fraction of B. crispa pos-
sesses analgesic and anti-inflammatory properties. B.
crispa produced marked inhibition of the pain response in
animals in chemical (acetic acid, formalin)- induced pain
models. B. crispa also produced profound anti-phlogistic
effect similar to standard drugs diclofenac sodium. The
plant extract produced significant inhibition of arachi-
donic acid induced platelets aggregation. These finding
suggest that B. crispa plant extract contains constituents
with peripheral analgesic and anti-inflammatory proper-
ties. These finding validates the folkloric use of B. crispa
and related species in the management of pain and inflam-
matory conditions. B. crispa could serve a natural resource
for the discovery of novel compounds effective in pain
and inflammatory conditions.
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